MetLife Investment Management LLC Has $1.03 Million Holdings in Dynavax Technologies Corporation $DVAX

MetLife Investment Management LLC lessened its stake in Dynavax Technologies Corporation (NASDAQ:DVAX) by 1.6% in the 1st quarter, Holdings Channel reports. The institutional investor owned 79,595 shares of the biopharmaceutical company’s stock after selling 1,288 shares during the quarter. MetLife Investment Management LLC’s holdings in Dynavax Technologies were worth $1,032,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in DVAX. Invesco Ltd. boosted its holdings in shares of Dynavax Technologies by 33.8% in the first quarter. Invesco Ltd. now owns 2,207,631 shares of the biopharmaceutical company’s stock valued at $28,633,000 after buying an additional 558,046 shares during the period. D. E. Shaw & Co. Inc. boosted its holdings in shares of Dynavax Technologies by 34.0% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,918,340 shares of the biopharmaceutical company’s stock valued at $24,497,000 after buying an additional 486,981 shares during the period. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Dynavax Technologies in the first quarter valued at approximately $4,370,000. Walleye Capital LLC boosted its holdings in shares of Dynavax Technologies by 50,734.1% in the first quarter. Walleye Capital LLC now owns 266,879 shares of the biopharmaceutical company’s stock valued at $3,461,000 after buying an additional 266,354 shares during the period. Finally, Cubist Systematic Strategies LLC acquired a new position in shares of Dynavax Technologies in the fourth quarter valued at approximately $2,485,000. Institutional investors and hedge funds own 96.96% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently commented on DVAX. JMP Securities restated a “market outperform” rating and set a $32.00 target price on shares of Dynavax Technologies in a report on Friday, August 22nd. Wall Street Zen raised shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Dynavax Technologies has a consensus rating of “Moderate Buy” and an average target price of $24.33.

Dynavax Technologies Stock Performance

Shares of DVAX stock opened at $10.06 on Friday. The stock has a market cap of $1.18 billion, a P/E ratio of -21.87 and a beta of 1.24. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.65 and a quick ratio of 6.01. The company has a fifty day moving average price of $10.63 and a two-hundred day moving average price of $11.22. Dynavax Technologies Corporation has a one year low of $9.22 and a one year high of $14.63.

Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of $0.12 by $0.02. The firm had revenue of $95.44 million during the quarter, compared to analysts’ expectations of $87.55 million. Dynavax Technologies had a negative net margin of 16.67% and a positive return on equity of 5.10%. As a group, equities analysts predict that Dynavax Technologies Corporation will post 0.32 EPS for the current year.

Insider Buying and Selling

In other news, Director Scott Dunseth Myers purchased 3,800 shares of the business’s stock in a transaction on Friday, August 22nd. The stock was purchased at an average price of $10.82 per share, for a total transaction of $41,116.00. Following the completion of the purchase, the director directly owned 35,004 shares in the company, valued at $378,743.28. The trade was a 12.18% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 2.98% of the stock is currently owned by corporate insiders.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.